JPH09508113A - 四環式誘導体、製造方法および用途 - Google Patents
四環式誘導体、製造方法および用途Info
- Publication number
- JPH09508113A JPH09508113A JP7519339A JP51933995A JPH09508113A JP H09508113 A JPH09508113 A JP H09508113A JP 7519339 A JP7519339 A JP 7519339A JP 51933995 A JP51933995 A JP 51933995A JP H09508113 A JPH09508113 A JP H09508113A
- Authority
- JP
- Japan
- Prior art keywords
- pyrido
- alkyl
- indole
- pyrazino
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 下記式(I)の化合物並びにその塩および溶媒和物。 (上記式中: R0は水素、ハロゲンまたはC1-6アルキルを表し、 R1は水素、C1-6アルキル、C2-6アルケニル、C2-6アルキニル、ハロC1-6 アルキル、C3-8シクロアルキル、C3-8シクロアルキルC1-3アルキル、アリー ルC1-3アルキルまたはヘテロアリールC1-3アルキルを表し、 R2はベンゼン、チオフェン、フランおよびピリジンから選択される場合によ り置換された単環式芳香族環、またはベンゼン環炭素原子の1つによって分子の 残りに結合される場合により置換された二環式環 (縮合環Aは飽和されているかまたは一部もしくは全部不飽和である5または6 員環であって、炭素原子並びに場合により酸素、イオウおよび窒素から選択され る1または2つのヘテロ原子からなる)を表し、および R3は水素またはC1-3アルキルを表すか、あるいはR1およびR3は一緒になっ て3または4員アルキルまたはアルケニル鎖を表す) 2. 下記式(Ia)の化合物並びにその塩および溶媒和物。 (上記式中: R0は水素、ハロゲンまたはC1-6アルキルを表し、 R1は水素、C1-6アルキル、ハロC1-6アルキル、C3-8シクロアルキル、C3- 8 シクロアルキルC1-3アルキル、アリールC1-3アルキルまたはヘテロアリール C1-3アルキルを表し、および R2はベンゼン、チオフェン、フランおよびピリジンから選択される場合によ り置換された単環式芳香族環、またはベンゼン環炭素原子の1つによって分子の 残りに結合される場合により置換された二環式環 (縮合環Aは飽和されているかまたは一部もしくは全部不飽和である5または6 員環であって、炭素原子並びに場合により酸素、イオウおよび窒素から選択され る1または2つのヘテロ原子からなる)を表す) 3. R0が水素を表す、請求項1または2に記載の化合物。 4. R1が水素、C1-4アルキル、ハロC1-4アルキル、C3-6シクロアルキル 、C3-6シクロアルキルメチル、ピリジルC1-3アルキル、フリルC1-3アルキル または場合により置換されたベンジルを表す、請求項1〜3のいずれか一項に記 載の化合物。 5. R1およびR3が一緒になって3員アルキル鎖を表す、請求項1〜3のい ずれか一項に記載の化合物。 6. R3が水素を表す、請求項1〜4のいずれか一項に記載の化合物。 7. R2が場合により置換されたベンゼン、チオフェン、フラン、ピリジン またはナフタレン環、あるいは場合により置換された二環式環 (上記式中、nは1または2であり、XおよびYは各々CH2またはOである) を表す、請求項1〜6のいずれか一項に記載の化合物。 8. 下記式(Ib)で表される式(I)のシス異性体 (上記式中、R0は水素またはハロゲンであり、R1、R2およびR3は前記請求項 で定義されたとおりである)およびラセミ混合物を含めたそのシス光学エナンチ オマーとの混合物、並びにこれら化合物の塩および溶媒和物。 9. シス‐2,3,6,7,12,12a‐ヘキサヒドロ‐2‐(4‐ピリ ジルメチル)‐6‐(3,4‐メチレンジオキシフェニル)‐ピラジノ〔2′, 1′:6,1〕ピリド〔3,4‐b〕インドール‐1,4‐ジオン; シス‐2,3,6,7,12,12a‐ヘキサヒドロ‐6‐(2,3‐ジヒド ロベンゾ〔b〕フラン‐5‐イル)‐2‐メチル‐ピラジノ〔2′,1′:6, 1〕ピリド〔3,4‐b〕インドール‐1,4‐ジオン; シス‐2,3,6,7,12,12a‐ヘキサヒドロ‐6‐(5‐ブロモ‐2 ‐チエニル)‐2‐メチル‐ピラジノ〔2′,1′:6,1〕ピリド〔3,4‐ b〕インドール‐1,4‐ジオン; シス‐2,3,6,7,12,12a‐ヘキサヒドロ‐2‐ブチル‐6‐(4 ‐メチルフェニル)‐ピラジノ〔2′,1′:6,1〕ピリド〔3,4‐b〕イ ンドール‐1,4‐ジオン; (6R,12aR)‐2,3,6,7,12,12a‐ヘキサヒドロ‐2‐イ ソプロピル‐6‐(3,4‐メチレンジオキシフェニル)‐ピラジノ〔2′,1 ′:6,1〕ピリド〔3,4‐b〕インドール‐1,4‐ジオン; (6R,12aR)‐2,3,6,7,12,12a‐ヘキサヒドロ‐2‐シ クロペンチル‐6‐(3,4‐メチレンジオキシフェニル)‐ピラジノ〔2′, 1′:6,1〕ピリド〔3,4‐b〕インドール‐1,4‐ジオン; (6R,12aR)‐2,3,6,7,12,12a‐ヘキサヒドロ‐2‐シ クロプロピルメチル‐6‐(4‐メトキシフェニル)‐ピラジノ〔2′,1′: 6,1〕ピリド〔3,4‐b〕インドール‐1,4‐ジオン; (6R,12aR)‐2,3,6,7,12,12a‐ヘキサヒドロ‐6‐( 3‐クロロ‐4‐メトキシフェニル)‐2‐メチル‐ピラジノ〔2′,1′:6 ,1〕ピリド〔3,4‐b〕インドール‐1,4‐ジオン; (6R,12aR)‐2,3,6,7,12,12a‐ヘキサヒドロ‐2‐メ チル‐6‐(3,4‐メチレンジオキシフェニル)‐ピラジノ〔2′,1′:6 ,1〕ピリド〔3,4‐b〕インドール‐1,4‐ジオン; (6R,12aR)‐2,3,6,7,12,12a‐ヘキサヒドロ‐6‐( 3,4‐メチレンジオキシフェニル)‐ピラジノ〔2′,1′:6,1〕ピリド 〔3,4‐b〕インドール‐1,4‐ジオン; (5aR,12R,14aS)‐1,2,3,5,6,11,12,14a‐ オクタヒドロ‐12‐(3,4‐メチレンジオキシフェニル)‐ピロロ〔1″, 2″:4′,5′〕ピラジノ〔2′,1′:6,1〕ピリド〔3,4‐b〕イン ドール‐5‐1,4‐ジオン; 並びにそれらの生理学上許容される塩および溶媒和物。 10. (6R,12aR)‐2,3,6,7,12,12a‐ヘキサヒドロ ‐2‐メチル‐6‐(3,4‐メチレンジオキシフェニル)‐ピラジノ〔2′, 1′:6,1〕ピリド〔3,4‐b〕インドール‐1,4‐ジオン 並びにその生理学上許容される塩および溶媒和物。 11. 安定、不安定および変種狭心症(angina)、高血圧、肺高血圧、慢性 閉塞性肺疾患、うっ血性心不全、腎不全、アテローム性動脈硬化症、血管開通性 減少症状、末梢血管疾患、血管障害、炎症疾患、発作、気管支炎、慢性喘息、ア レルギー喘息、アレルギー性鼻炎、緑内障または腸運動の障害で特徴付けられる 疾患の治療に用いられる、請求項1〜10のいずれか一項に記載の化合物。 12. 安定、不安定および変種狭心症(angina)、高血圧、肺高血圧、慢性 閉塞性肺疾患、うっ血性心不全、腎不全、アテローム性動脈硬化症、血管開通性 減少症状、末梢血管疾患、血管障害、炎症疾患、発作、気管支炎、慢性喘息、ア レルギー喘息、アレルギー性鼻炎、緑内障または腸運動の障害で特徴付けられる 疾患の治療用薬剤の製造への、請求項1〜10のいずれか一項に記載の化合物の 使用。 13. 請求項1〜10のいずれか一項に記載の化合物の治療上有効量を体に 投与することからなる、ヒトまたは非ヒト動物体における安定、不安定および変 種狭心症(angina)、高血圧、肺高血圧、慢性閉塞性肺疾患、うっ血性心不全、 腎不全、アテローム性動脈硬化症、血管開通性減少症状、末梢血管疾患、血管障 害、炎症疾患、発作、気管支炎、慢性喘息、アレルギー喘息、アレルギー性鼻炎 、緑内障または腸運動の障害で特徴付けられる疾患の治療方法。 14. 請求項1〜10のいずれか一項に記載の化合物をその薬学上許容され る希釈物またはキャリアと一緒に含んでなる医薬組成物。 15. 請求項1〜10のいずれか一項に記載の化合物をそのための薬学上許 容される希釈物またはキャリアと一緒に混合することからなる、上記化合物を含 んでなる医薬組成物の製造方法。 16. R3が水素を表す式(I)の化合物を製造するための方法(A)(方 法(A)では下記式(II)の化合物 (上記式中AlkはC1-6アルキルを表し、Halはハロゲン原子である)を一 級アミンR1NH2で処理する)、または R1およびR3が一緒になって3または4員アルキルまたはアルケニル鎖を表す 式(I)の化合物を製造するための方法(B)(方法(B)は下記式(VIII)の化 合物 (上記式中AlkはC1-6アルキルを表し、R1およびR3は一緒になって前記の ような3または4員鎖双方を表す)の環化からなる)、または R3がC1-3アルキルを表す式(I)の化合物を製造するための方法(C)(方 法(C)は下記式(X)の化合物 (上記式中AlkはC1-6アルキルを表し、R5はハロゲン原子によりC1におい て置換されたC2-5アルキルを表す)の環化からなる)、または 前記のような方法(A)、(B)または(C)に続く i)変換工程および/または ii)塩形成、または iii)溶媒和物形成 からなる、式(I)の化合物の製造方法。 17. R0が水素、R2がフェニルおよびAlkがメチルである化合物(III) 、(V)、(VI)および(VII)を除いた、式(II)、(III)、(V)、(VI)、(V II)、(VIII)および(X)の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9401090.7 | 1994-01-21 | ||
GB9401090A GB9401090D0 (en) | 1994-01-21 | 1994-01-21 | Chemical compounds |
PCT/EP1995/000183 WO1995019978A1 (en) | 1994-01-21 | 1995-01-19 | Tetracyclic derivatives, process of preparation and use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004125881A Division JP4347125B2 (ja) | 1994-01-21 | 2004-04-21 | 四環式誘導体の中間体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09508113A true JPH09508113A (ja) | 1997-08-19 |
JP3808095B2 JP3808095B2 (ja) | 2006-08-09 |
Family
ID=10749089
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51933995A Expired - Lifetime JP3808095B2 (ja) | 1994-01-21 | 1995-01-19 | 四環式誘導体、製造方法および用途 |
JP2004125881A Expired - Lifetime JP4347125B2 (ja) | 1994-01-21 | 2004-04-21 | 四環式誘導体の中間体 |
JP2009006669A Withdrawn JP2009102386A (ja) | 1994-01-21 | 2009-01-15 | 四環式誘導体の中間体 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004125881A Expired - Lifetime JP4347125B2 (ja) | 1994-01-21 | 2004-04-21 | 四環式誘導体の中間体 |
JP2009006669A Withdrawn JP2009102386A (ja) | 1994-01-21 | 2009-01-15 | 四環式誘導体の中間体 |
Country Status (49)
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002543116A (ja) * | 1999-04-30 | 2002-12-17 | リリー アイコス リミテッド ライアビリティ カンパニー | 単位製剤 |
JP2004501124A (ja) * | 2000-06-07 | 2004-01-15 | リリー アイコス リミテッド ライアビリティ カンパニー | 化合物 |
JP2004501920A (ja) * | 2000-06-23 | 2004-01-22 | リリー アイコス リミテッド ライアビリティ カンパニー | 環状gmp特異的ホスホジエステラーゼ阻害剤 |
WO2004113300A1 (ja) * | 2003-06-23 | 2004-12-29 | Ono Pharmaceutical Co., Ltd. | 新規三環性複素環化合物 |
JP2005511626A (ja) * | 2001-11-14 | 2005-04-28 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | ホスホジエステラーゼ阻害剤として有用な置換された四環式ピロロキノロン誘導体 |
US7964726B2 (en) | 2004-12-22 | 2011-06-21 | Ono Pharmaceutical Co., Ltd. | Tricyclic compound and use thereof |
JP2018517720A (ja) * | 2015-06-26 | 2018-07-05 | 重▲慶▼文理学院 | 新規ホスホジエステラーゼ5阻害剤とその使用 |
Families Citing this family (205)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9514465D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
GB9511220D0 (en) * | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
US6060477A (en) | 1995-06-07 | 2000-05-09 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives |
US6262059B1 (en) | 1995-06-07 | 2001-07-17 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with quinazoline derivatives |
US6232312B1 (en) | 1995-06-07 | 2001-05-15 | Cell Pathways, Inc. | Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides |
US5874440A (en) | 1995-06-07 | 1999-02-23 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives |
US6200980B1 (en) | 1995-06-07 | 2001-03-13 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl purinone derivatives |
US6046216A (en) | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives |
GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
GB9514473D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
YU49898A (sh) * | 1996-05-10 | 2000-03-21 | Icos Corporation | Hemijska jedinjenja |
US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6071934A (en) | 1997-03-25 | 2000-06-06 | Cell Pathways, Inc. | Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions |
AU756136B2 (en) | 1997-06-23 | 2003-01-02 | Queen's University At Kingston | Microdose therapy |
US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US6046199A (en) * | 1998-01-14 | 2000-04-04 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives |
US6410584B1 (en) | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
US6268372B1 (en) | 1998-09-11 | 2001-07-31 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones |
US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
IL132406A0 (en) * | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
US6133271A (en) | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
US6348032B1 (en) | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
US6211220B1 (en) | 1998-11-23 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
US6211177B1 (en) | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
US6420410B1 (en) | 1998-11-24 | 2002-07-16 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones |
US6358992B1 (en) | 1998-11-25 | 2002-03-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with indole derivatives |
ES2213004T3 (es) | 1999-03-24 | 2004-08-16 | Harbor Branch Oceanographic Institution, Inc. | Usos antiinflamatorios de manzaminas. |
US6943166B1 (en) | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
US6451807B1 (en) | 1999-04-30 | 2002-09-17 | Lilly Icos, Llc. | Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor |
US7235625B2 (en) | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
DZ3179A1 (fr) | 1999-08-03 | 2001-02-08 | Lilly Icos Llc | Compositions pharmaceutiques à base de beta-carboline. |
CA2387353A1 (en) | 1999-10-11 | 2001-04-19 | Charlotte Moira Norfor Allerton | Pharmaceutically active compounds |
TWI224966B (en) * | 1999-11-02 | 2004-12-11 | Pfizer | Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient |
US6562830B1 (en) | 1999-11-09 | 2003-05-13 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives |
US6376489B1 (en) * | 1999-12-23 | 2002-04-23 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
CN1436080A (zh) | 2000-04-19 | 2003-08-13 | 利利艾科斯有限公司 | 环gmp-特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途 |
UA74826C2 (en) * | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
UA72611C2 (uk) * | 2000-05-17 | 2005-03-15 | Орто-Макнейл Фармацевтикал, Інк. | Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази |
DE60121048T2 (de) | 2000-06-23 | 2007-01-25 | Lilly Icos Llc, Wilmington | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE |
WO2002000657A2 (en) * | 2000-06-26 | 2002-01-03 | Lilly Icos Llc | Condensed pyrazindione derivatives |
IL153928A0 (en) * | 2000-07-24 | 2003-07-31 | Bayer Cropscience Ag | Biphenyl carboxamides |
EP1305313A1 (en) | 2000-08-02 | 2003-05-02 | Lilly Icos LLC | Fused heterocyclic derivatives as phosphodiesterase inhibitors |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
EP1335917B1 (en) | 2000-10-02 | 2005-08-24 | Lilly Icos LLC | Condensed pyridoindole derivatives |
AU2001292698A1 (en) * | 2000-10-02 | 2002-04-15 | Lilly Icos Llc | Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction |
US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
EP1211313A3 (en) * | 2000-11-01 | 2003-04-23 | Pfizer Limited | Modulation of PDE11A activity |
US6828473B2 (en) | 2000-11-01 | 2004-12-07 | Pfizer Inc. | Modulation of PDE11A activity |
DE60122559T2 (de) * | 2000-11-06 | 2006-12-07 | Lilly Icos Llc, Wilmington | Indolderivate als pde5-inhibitoren |
CA2441792C (en) * | 2001-04-25 | 2010-08-03 | Lilly Icos Llc | Carboline derivatives as inhibitors of phosphodiesterase 5 (pdes) for the treatment of cardiovascular diseases and erectile dysfunction |
WO2002098875A1 (en) * | 2001-06-05 | 2002-12-12 | Lilly Icos Llc | Carboline derivatives as pde-5 inhibitors |
WO2002098877A1 (en) * | 2001-06-05 | 2002-12-12 | Lilly Icos Llc | Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives |
ATE360422T1 (de) * | 2001-06-05 | 2007-05-15 | Lilly Icos Llc | Tetrazyklische verbindungen als pde5-inhibitoren |
EP1397361B1 (en) * | 2001-06-21 | 2006-08-09 | Lilly Icos LLC | Carboline derivatives as pdev inhibitors |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
EP1442042A1 (en) * | 2001-11-09 | 2004-08-04 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
BR0311191A (pt) * | 2002-05-23 | 2005-03-01 | Pfizer | Combinação |
EP1719772A1 (en) | 2002-05-31 | 2006-11-08 | Schering Corporation | Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof |
GB0214784D0 (en) * | 2002-06-26 | 2002-08-07 | Pfizer Ltd | Novel combination |
AU2003256539B2 (en) * | 2002-07-31 | 2010-03-04 | Icos Corporation | Modified pictet-spengler reaction and products prepared therefrom |
GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
ES2341240T3 (es) | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
MXPA05010373A (es) | 2003-04-01 | 2005-12-05 | Applied Research Systems | Inhibidores de fosfodiesterasas en infertilidad. |
EP1620437B1 (en) | 2003-04-29 | 2009-06-17 | Pfizer Limited | 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension |
EA012279B1 (ru) * | 2003-05-22 | 2009-08-28 | Никомед Гмбх | Композиция, включающая ингибитор pde4 и ингибитор pde5 |
WO2005016244A2 (en) * | 2003-06-13 | 2005-02-24 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
WO2005058280A2 (en) * | 2003-12-12 | 2005-06-30 | Myogen, Inc. | Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
WO2005068464A2 (en) * | 2003-12-15 | 2005-07-28 | Cadila Healthcare Limited | Process for preparing tadalafil and its intermediates |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
JP2007530566A (ja) * | 2004-03-22 | 2007-11-01 | ミオゲン インコーポレイティッド | (r)−エノキシモンスルホキシドおよびpde−iii媒介疾患の治療におけるその使用 |
CA2560528A1 (en) * | 2004-03-22 | 2005-10-06 | Myogen, Inc. | (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases |
DE602005011784D1 (de) | 2004-04-07 | 2009-01-29 | Pfizer | Pyrazoloä4,3-düpyrimidine |
WO2005116030A1 (en) * | 2004-05-31 | 2005-12-08 | Matrix Laboratories Ltd | A process for the preparation of tadalafil |
WO2006007213A1 (en) * | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
CA2577442A1 (en) | 2004-08-17 | 2006-03-02 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for treating cardiac indications |
WO2006049986A1 (en) * | 2004-10-28 | 2006-05-11 | Dr. Reddy's Laboratories Ltd. | Polymorphic forms of tadalafil |
WO2006050458A2 (en) * | 2004-11-02 | 2006-05-11 | Teva Pharmaceutical Industries, Ltd. | Tadalafil crystal forms and processes for preparing them |
AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
US7417044B2 (en) | 2005-02-25 | 2008-08-26 | Teva Pharmaceutical Industries Ltd. | Tadalafil having a large particle size and a process for preparation thereof |
MX2007010431A (es) * | 2005-02-25 | 2007-10-11 | Teva Pharma | Proceso para purificar tadalafil. |
CA2596667A1 (en) * | 2005-02-25 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Process of synthesizing tadalafil |
US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
MX2007012607A (es) * | 2005-04-12 | 2008-01-11 | Teva Pharma | Preparacion de intermedios de tadalafil. |
ME01609B (me) | 2005-04-19 | 2014-09-20 | Takeda Gmbh | Roflumilast za liječenje pulmonarne hipertenzije |
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
EP1881985B1 (en) | 2005-05-12 | 2010-12-29 | Pfizer, Inc. | Anhydrous crystalline forms of n-ý1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl¨methanesulfonamide |
US20070010525A1 (en) * | 2005-06-27 | 2007-01-11 | Meyer Jackson | Method and compositions for modulating neuropeptide hormone secretion |
BRPI0615972A2 (pt) * | 2005-07-29 | 2011-05-31 | Concert Pharmaceuticals Inc | composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto |
US7863274B2 (en) * | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
WO2007014929A1 (en) | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Use of flibanserin in the treatment of obesity |
WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP1937217A2 (en) * | 2005-09-13 | 2008-07-02 | Elan Pharma International Limited | Nanoparticulate tadalafil formulations |
WO2007044976A2 (en) | 2005-10-12 | 2007-04-19 | Unimed Pharmaceuticals, Llc | Improved testosterone gel and method of use |
JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス,インコーポレイティド | Pde阻害による神経新生の調節 |
EP1945214A1 (en) | 2005-10-29 | 2008-07-23 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
WO2007100387A2 (en) * | 2005-11-03 | 2007-09-07 | Dr. Reddy's Laboratories Ltd. | Process for preparing tadalafil |
EP2218442A1 (en) | 2005-11-09 | 2010-08-18 | CombinatoRx, Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
US7202229B1 (en) * | 2005-12-30 | 2007-04-10 | Alan James Group, Llc. | Aspirin formulation for cardiovascular health |
US7201929B1 (en) * | 2005-12-30 | 2007-04-10 | Alan James Group, Llc. | Aspirin formulation for cardiovascular health |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP1991212A1 (en) * | 2006-03-08 | 2008-11-19 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007110734A1 (en) * | 2006-03-24 | 2007-10-04 | Glenmark Pharmaceuticals Limited | Process for the preparation of tadalafil |
US20080027072A1 (en) * | 2006-04-20 | 2008-01-31 | Ampla Pharmaceuticals, Inc. | Potentiation of MC4 receptor activity |
EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
US20090291958A1 (en) * | 2006-06-08 | 2009-11-26 | Auspex Pharmaceuticals, Inc. | Substituted PDE5 inhibitors |
ES2336719T3 (es) | 2006-06-30 | 2010-04-15 | Boehringer Ingelheim International Gmbh | Flibanserina para el tratamiento de la incontinencia urinaria y las enfermedades relacionadas. |
MX2008016569A (es) * | 2006-07-07 | 2009-01-30 | Teva Pharma | Composiciones solidas que contienen tadalafil y al menos un portador. |
AU2007275634B2 (en) | 2006-07-21 | 2011-01-20 | Novartis Ag | Formulations for benzimidazolyl pyridyl ethers |
BRPI0716439B8 (pt) | 2006-08-14 | 2021-05-25 | Boehringer Ingelheim Int | sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos |
AR062321A1 (es) | 2006-08-25 | 2008-10-29 | Boehringer Ingelheim Int | Sistema de liberacion controlada y metodo para fabricarlo |
AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
CA2663347A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
SI2101777T1 (sl) | 2006-12-12 | 2015-08-31 | Gilead Sciences, Inc. | Sestavek za zdravljenje pljučne hipertenzije |
WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
PL2114147T3 (pl) | 2007-02-12 | 2012-10-31 | Vyrix Pharmaceuticals Inc | Zmniejszanie skutków ubocznych tramadolu |
KR20090121315A (ko) | 2007-02-12 | 2009-11-25 | 디엠아이 바이오사이언시스 인코포레이티드 | 조루 및 발기부전을 동시에 치료하는 방법 |
WO2008103470A2 (en) * | 2007-02-21 | 2008-08-28 | Trustees Of Columbia University In The City Of New York | Oncogenic-ras-signal dependent lethal compounds |
CA2685184A1 (en) * | 2007-04-25 | 2008-11-06 | Teva Pharmaceutical Industries Ltd. | Solid dosage forms |
FR2916200A1 (fr) * | 2007-05-18 | 2008-11-21 | Fourtillan Snc | Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique |
DE102007028869A1 (de) * | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
PT2170880E (pt) | 2007-06-29 | 2012-10-29 | Ranbaxy Lab Ltd | Processo para a preparação de intermediários de compostos tetracíclicos |
EP2033962A1 (en) * | 2007-08-22 | 2009-03-11 | 4Sc Ag | Tetracyclic indolopyridines as EG5 inhibitors |
UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
WO2009091777A1 (en) * | 2008-01-15 | 2009-07-23 | Forest Laboratories Holdings Limited | Nebivolol in the treatment of sexual dysfunction |
ITMI20080285A1 (it) * | 2008-02-22 | 2009-08-23 | Endura Spa | Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici |
EP2107059A1 (en) | 2008-03-31 | 2009-10-07 | LEK Pharmaceuticals D.D. | Conversion of tryptophan into ß-carboline derivatives |
PL385356A1 (pl) | 2008-06-03 | 2009-12-07 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania tadalafilu |
US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
EP2181997A1 (en) | 2008-10-30 | 2010-05-05 | Chemo Ibérica, S.A. | A process for the preparation of tadalafil |
DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
EP2379076B1 (en) | 2008-12-23 | 2014-11-12 | The Trustees of Columbia University in the City of New York | Phosphodiesterase inhibitors and uses thereof |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
JP6074142B2 (ja) | 2009-02-26 | 2017-02-01 | タール ファーマシューティカルズ,インコーポレイテッド | 医薬化合物の結晶化 |
GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
DE102009033396A1 (de) | 2009-07-16 | 2011-01-20 | Ratiopharm Gmbh | Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung |
UY33041A (es) | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
US20110136815A1 (en) * | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
JP2013523809A (ja) | 2010-04-05 | 2013-06-17 | エスケー ケミカルズ カンパニー リミテッド | Pde5抑制剤を含む皮膚しわ改善用組成物 |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
KR20130069855A (ko) | 2010-10-15 | 2013-06-26 | 길리애드 사이언시즈, 인코포레이티드 | 폐 고혈압 치료의 조성물 및 방법 |
WO2012107092A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
ES2541421T3 (es) | 2011-02-10 | 2015-07-20 | Interquim, S.A. | Procedimiento de obtención de compuestos derivados de tetrahidro-ß-carbolina |
WO2012107541A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
WO2012107090A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Granulated composition comprising tadalafil and a disintegrant |
US20120123124A1 (en) * | 2011-04-22 | 2012-05-17 | Drug Process Licensing Associates, LLC | Manufacturing process for Tadalafil from racemic or L-tryptophan |
CN102180876B (zh) * | 2011-05-28 | 2016-05-18 | 浙江华海药业股份有限公司 | 一种他达那非晶型i的制备方法 |
EP2535049A1 (en) | 2011-06-17 | 2012-12-19 | Proyecto de Biomedicina Cima, S.L. | Tadalafil for the treatment of dementia |
CN102367253B (zh) * | 2011-09-20 | 2016-04-06 | 浙江华海药业股份有限公司 | 一种制备他达拉非晶型a的方法 |
WO2013067309A1 (en) | 2011-11-04 | 2013-05-10 | Xion Pharmaceutical Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
WO2013109738A1 (en) | 2012-01-17 | 2013-07-25 | The Trustees Of Columbia University In The City Of New York | Novel phosphodiesterase inhibitors and uses thereof |
WO2013109227A1 (en) | 2012-01-18 | 2013-07-25 | Mahmut Bilgic | Pharmaceutical compositions comprising ceftibuten |
WO2014092661A1 (en) | 2012-01-18 | 2014-06-19 | Mahmut Bilgic | Particulate formulations of tadalafil in effervescent form |
WO2013109223A1 (en) | 2012-01-18 | 2013-07-25 | Mahmut Bilgic | Particulate formulations of tadalafil in effervescent form |
CN104168895B (zh) | 2012-02-28 | 2020-02-21 | 首尔制药株式会社 | 包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜 |
WO2014055801A1 (en) | 2012-10-05 | 2014-04-10 | Henkin Robert I | Phosphodiesterase inhibitors for treating taste and smell disorders |
EP3981409A1 (en) | 2012-12-04 | 2022-04-13 | Aribio Inc. | Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells |
KR101953735B1 (ko) | 2012-12-14 | 2019-03-04 | 한미약품 주식회사 | 포스포다이에스터라제-5 억제제를 포함하는 츄정 |
ES2700989T3 (es) | 2012-12-21 | 2019-02-20 | Mayo Found Medical Education & Res | Métodos y materiales para tratar estenosis de la válvula aórtica calcificada |
SG11201506211RA (en) | 2013-02-21 | 2015-09-29 | Adverio Pharma Gmbh | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
CN103232451A (zh) * | 2013-05-14 | 2013-08-07 | 张家港威胜生物医药有限公司 | 一种他达那非的简易制备工艺 |
WO2015009930A2 (en) | 2013-07-17 | 2015-01-22 | The Trustees Of Columbia University In The City Of New York | Novel phosphodiesterase inhibitors and uses thereof |
WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
WO2015126944A1 (en) | 2014-02-18 | 2015-08-27 | Henkin Robert I | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
AR099416A1 (es) | 2014-02-28 | 2016-07-20 | Lilly Co Eli | Terapia combinada para la hipertensión resistente |
MX2016014384A (es) | 2014-06-23 | 2017-01-20 | Celgene Corp | Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado. |
EP2962684A1 (en) | 2014-06-30 | 2016-01-06 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally disintegrating formulations of tadalafil |
ES2784251T3 (es) | 2014-06-30 | 2020-09-23 | Montero Gida Sanayi Ve Ticaret As | Formulaciones de disgregación por vía oral de tadalafilo |
CN104086546B (zh) * | 2014-07-14 | 2016-08-17 | 福建广生堂药业股份有限公司 | 他达拉非的药用酸盐及其制备方法 |
WO2016012539A1 (en) | 2014-07-23 | 2016-01-28 | Krka, D.D., Novo Mesto | A process for the preparation of cgmp-phosphodiesterase inhibitor and oral pharmaceutical formulation comprising tadalafil co-precipitates |
KR101645652B1 (ko) | 2014-11-03 | 2016-08-08 | (주)퓨젠바이오농업회사법인 | 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물 |
CN105541840B (zh) * | 2015-12-31 | 2017-12-05 | 湖南千金湘江药业股份有限公司 | 关键中间体及其合成方法和在制备他达拉非方面的应用 |
CN105541835B (zh) * | 2015-12-31 | 2017-12-05 | 湖南千金湘江药业股份有限公司 | 顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用 |
EP3554507A1 (en) | 2016-12-14 | 2019-10-23 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
CN106977516B (zh) * | 2017-03-02 | 2019-06-18 | 山东裕欣药业有限公司 | 一种他达拉非的制备方法 |
RU2692764C1 (ru) | 2019-04-26 | 2019-06-27 | Общество с ограниченной ответственностью "Балтфарма" | Способ получения тадалафила |
CN111995658B (zh) * | 2019-05-27 | 2022-08-02 | 首都医科大学 | Ldv修饰的五环哌嗪二酮及其制备和应用 |
MX2021015425A (es) | 2019-07-15 | 2022-02-21 | Biolab Sanus Farmaceutica Ltda | Estereoisomeros del compuesto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hi droxipropano-2-il)-1-(1h-indol-3-il)-6,7-dihidro-3h-oxazol[3,4-a] pirazina-5,8-diona y su uso como antitumoral y inhibidor de la enzima fosfodiesterasa. |
CN110606847A (zh) * | 2019-07-30 | 2019-12-24 | 中国医药集团总公司四川抗菌素工业研究所 | 一种他达拉非顺式中间体的制备方法及其应用 |
WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3644384A (en) * | 1969-06-09 | 1972-02-22 | Sterling Drug Inc | Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives |
US3717638A (en) * | 1971-03-11 | 1973-02-20 | Sterling Drug Inc | 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR |
US3917599A (en) * | 1973-03-30 | 1975-11-04 | Council Scient Ind Res | 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles |
GB1454171A (en) * | 1973-10-19 | 1976-10-27 | Council Scient Ind Res | Tetracyclic compounds |
US4273773A (en) * | 1979-09-24 | 1981-06-16 | American Home Products Corporation | Antihypertensive tricyclic isoindole derivatives |
EP0357122A3 (en) * | 1988-08-29 | 1991-10-23 | Duphar International Research B.V | Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties |
DE3830096A1 (de) * | 1988-09-03 | 1990-03-15 | Hoechst Ag | Piperazindione mit psychotroper wirkung |
GB9514465D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
US6046199A (en) * | 1998-01-14 | 2000-04-04 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives |
US6225315B1 (en) * | 1998-11-30 | 2001-05-01 | Pfizer Inc | Method of treating nitrate-induced tolerance |
-
1994
- 1994-01-21 GB GB9401090A patent/GB9401090D0/en active Pending
-
1995
- 1995-01-17 HR HR950023A patent/HRP950023B1/xx not_active IP Right Cessation
- 1995-01-17 IS IS4252A patent/IS1888B/is unknown
- 1995-01-18 TW TW084100415A patent/TW378210B/zh not_active IP Right Cessation
- 1995-01-18 MY MYPI95000109A patent/MY114663A/en unknown
- 1995-01-19 BR BRPI9506559A patent/BR9506559C8/pt not_active IP Right Cessation
- 1995-01-19 AT AT95907565T patent/ATE169018T1/de active
- 1995-01-19 ES ES95907565T patent/ES2122543T3/es not_active Expired - Lifetime
- 1995-01-19 EE EE9600093A patent/EE03231B1/xx active Protection Beyond IP Right Term
- 1995-01-19 PE PE1995259855A patent/PE49495A1/es not_active IP Right Cessation
- 1995-01-19 HU HU9601982A patent/HU222494B1/hu active IP Right Grant
- 1995-01-19 CN CN95192078A patent/CN1045777C/zh not_active Expired - Lifetime
- 1995-01-19 DE DE69503753T patent/DE69503753T2/de not_active Expired - Lifetime
- 1995-01-19 JP JP51933995A patent/JP3808095B2/ja not_active Expired - Lifetime
- 1995-01-19 PL PL95315559A patent/PL179744B1/pl unknown
- 1995-01-19 RO RO96-01454A patent/RO117794B1/ro unknown
- 1995-01-19 EG EG4795A patent/EG25852A/xx active
- 1995-01-19 ZA ZA95424A patent/ZA95424B/xx unknown
- 1995-01-19 DE DE2003199006 patent/DE10399006I2/de active Active
- 1995-01-19 WO PCT/EP1995/000183 patent/WO1995019978A1/en active Search and Examination
- 1995-01-19 RU RU96117127A patent/RU2142463C1/ru active
- 1995-01-19 EP EP95907565A patent/EP0740668B1/en not_active Expired - Lifetime
- 1995-01-19 SK SK940-96A patent/SK280879B6/sk not_active IP Right Cessation
- 1995-01-19 MX MX9602904A patent/MX9602904A/es unknown
- 1995-01-19 CA CA002181377A patent/CA2181377C/en not_active Expired - Lifetime
- 1995-01-19 SI SI9530162T patent/SI0740668T1/xx unknown
- 1995-01-19 AU AU15748/95A patent/AU689205B2/en not_active Expired
- 1995-01-19 KR KR1019960703922A patent/KR100357411B1/ko not_active IP Right Cessation
- 1995-01-19 CO CO95001858A patent/CO4340684A1/es unknown
- 1995-01-19 AP APAP/P/1995/000712A patent/AP556A/en active
- 1995-01-19 NZ NZ279199A patent/NZ279199A/en not_active IP Right Cessation
- 1995-01-19 IL IL11238495A patent/IL112384A/en active Protection Beyond IP Right Term
- 1995-01-19 DK DK95907565T patent/DK0740668T3/da active
- 1995-01-19 US US08/669,389 patent/US5859006A/en not_active Expired - Lifetime
- 1995-01-19 CZ CZ19962116A patent/CZ286566B6/cs not_active IP Right Cessation
- 1995-01-19 SG SG1996007328A patent/SG49184A1/en unknown
- 1995-01-20 TN TNTNSN95004A patent/TNSN95004A1/fr unknown
- 1995-01-20 UY UY23893A patent/UY23893A1/es not_active IP Right Cessation
- 1995-01-20 MA MA23760A patent/MA23433A1/fr unknown
- 1995-01-20 IN IN77DE1995 patent/IN183942B/en unknown
- 1995-01-20 SV SV1995000002A patent/SV1995000002A/es active IP Right Grant
- 1995-01-31 SA SA95150475A patent/SA95150475B1/ar unknown
-
1996
- 1996-07-10 LV LVP-96-228A patent/LV11690B/lv unknown
- 1996-07-17 OA OA60864A patent/OA10584A/en unknown
- 1996-07-18 BG BG100727A patent/BG62733B1/bg unknown
- 1996-07-19 FI FI962927A patent/FI113176B/fi not_active IP Right Cessation
- 1996-07-19 NO NO963015A patent/NO306465B1/no not_active IP Right Cessation
-
1998
- 1998-06-26 AU AU73912/98A patent/AU707055B2/en not_active Expired
- 1998-08-12 US US09/133,078 patent/US6025494A/en not_active Expired - Lifetime
- 1998-12-01 CN CN98122779A patent/CN1070492C/zh not_active Expired - Lifetime
- 1998-12-22 HK HK98114572A patent/HK1013286A1/xx not_active IP Right Cessation
-
1999
- 1999-09-21 US US09/399,667 patent/US6127542A/en not_active Expired - Lifetime
-
2000
- 2000-08-07 US US09/633,431 patent/US6369059B1/en not_active Expired - Lifetime
-
2002
- 2002-02-05 US US10/068,114 patent/US6784179B2/en not_active Expired - Fee Related
-
2003
- 2003-01-22 NO NO2003002C patent/NO2003002I2/no not_active IP Right Cessation
- 2003-03-26 LU LU91017C patent/LU91017I2/fr unknown
- 2003-04-23 NL NL300124C patent/NL300124I2/nl unknown
-
2004
- 2004-04-21 JP JP2004125881A patent/JP4347125B2/ja not_active Expired - Lifetime
-
2009
- 2009-01-15 JP JP2009006669A patent/JP2009102386A/ja not_active Withdrawn
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002543116A (ja) * | 1999-04-30 | 2002-12-17 | リリー アイコス リミテッド ライアビリティ カンパニー | 単位製剤 |
JP2004501124A (ja) * | 2000-06-07 | 2004-01-15 | リリー アイコス リミテッド ライアビリティ カンパニー | 化合物 |
JP2004501920A (ja) * | 2000-06-23 | 2004-01-22 | リリー アイコス リミテッド ライアビリティ カンパニー | 環状gmp特異的ホスホジエステラーゼ阻害剤 |
JP2005511626A (ja) * | 2001-11-14 | 2005-04-28 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | ホスホジエステラーゼ阻害剤として有用な置換された四環式ピロロキノロン誘導体 |
WO2004113300A1 (ja) * | 2003-06-23 | 2004-12-29 | Ono Pharmaceutical Co., Ltd. | 新規三環性複素環化合物 |
US7872133B2 (en) | 2003-06-23 | 2011-01-18 | Ono Pharmaceutical Co., Ltd. | Tricyclic heterocycle compound |
US7964726B2 (en) | 2004-12-22 | 2011-06-21 | Ono Pharmaceutical Co., Ltd. | Tricyclic compound and use thereof |
US8476293B2 (en) | 2004-12-22 | 2013-07-02 | Ono Pharmaceutical Co., Ltd. | Tricyclic compound and use thereof |
US8952158B2 (en) | 2004-12-22 | 2015-02-10 | Ono Pharmaceutical Co., Ltd. | Tricyclic compound and use thereof |
JP2018517720A (ja) * | 2015-06-26 | 2018-07-05 | 重▲慶▼文理学院 | 新規ホスホジエステラーゼ5阻害剤とその使用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3808095B2 (ja) | 四環式誘導体、製造方法および用途 | |
US6143746A (en) | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use | |
US6001847A (en) | Chemical compounds | |
CA2226761A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
JP2004501919A (ja) | 化学化合物 | |
PT87604B (pt) | Processo para a preparacao de agentes anti-alergicos e anti-inflamatorios di-hidropiridinicos | |
US20020035111A1 (en) | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040121 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040421 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051020 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060302 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060418 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060517 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 3808095 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
S633 | Written request for registration of reclamation of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313633 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090526 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090526 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090526 Year of fee payment: 3 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160526 Year of fee payment: 10 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160526 Year of fee payment: 10 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160526 Year of fee payment: 10 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160526 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20180526 Year of fee payment: 12 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |